MIF4GD抗體,Rabbit Polyclonal MIF4GD Antibody

MIF4GD抗體—艾普蒂

價(jià)格	詢價(jià)
包裝	20μl	50μl	100μl

最小起訂量	1μl
發(fā)貨地	上海
更新日期	2025-05-20

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:MIF4GD抗體	英文名稱:Rabbit Polyclonal MIF4GD Antibody
品牌: 艾普蒂	產(chǎn)地: 武漢
保存條件: Stored at -20°C for 4657 year. Avoid repeated freeze / thaw cycles.	產(chǎn)品類別: 抗體
重組: 否	應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat	宿主: Rabbit
偶聯(lián)物: 無	靶點(diǎn): MIF4GD

驗(yàn)證與應(yīng)用

應(yīng)用及物種

WB	咨詢技術(shù)	Human,Mouse,Rat
IF	咨詢技術(shù)	Human,Mouse,Rat
IHC	1/50-1/200	Human,Mouse,Rat
ICC	技術(shù)咨詢	Human,Mouse,Rat
FCM	咨詢技術(shù)	Human,Mouse,Rat
Elisa	1/5000-1/10000	Human,Mouse,Rat

產(chǎn)品詳情

Aliases	GST2; GTA2; GTH2; GSTA2-2
Host/Isotype	Rabbit IgG
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Fusion protein of human GSTA2
Formulation	Purified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

The image is immunohistochemistry of paraffin-embedded Human brain tissue using P01063(GSTA2 Antibody) at dilution 1/50. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P01063(GSTA2 Antibody) at dilution 1/50. (Original magnification: ×200)

參考文獻(xiàn)

以下是關(guān)于MIF4GD抗體的假設(shè)性文獻(xiàn)示例(注：MIF4GD相關(guān)研究較為小眾，以下內(nèi)容為模擬參考，建議結(jié)合具體研究領(lǐng)域進(jìn)一步核實(shí))：

1. **"Structural characterization of MIF4GD-specific antibodies and their role in autoimmune disease modulation"**

*作者：Zhang L, et al. (2020)*

*摘要*：本研究報(bào)道了一種靶向MIF蛋白四聚體結(jié)構(gòu)域(MIF4GD)的單克隆抗體的開發(fā)，通過X射線晶體學(xué)解析了抗體-抗原復(fù)合物結(jié)構(gòu)，并證明該抗體可抑制MIF與CD74受體的結(jié)合，減輕實(shí)驗(yàn)性關(guān)節(jié)炎模型的炎癥反應(yīng)。

2. **"A novel anti-MIF4GD antibody inhibits tumor angiogenesis in glioblastoma models"**

*作者：Smith J, et al. (2018)*

*摘要*：文章描述了一種針對(duì)MIF4GD表位的人源化抗體，通過阻斷MIF介導(dǎo)的血管內(nèi)皮生長因子(VEGF)信號(hào)通路，顯著抑制膠質(zhì)母細(xì)胞瘤小鼠模型中的腫瘤血管生成和生長。

3. **"MIF4GD-specific nanobodies as potential therapeutics for sepsis-associated cytokine storm"**

*作者：Wang Y, et al. (2021)*

*摘要*：研究團(tuán)隊(duì)利用駱駝源納米抗體庫篩選出高親和力MIF4GD結(jié)合劑，實(shí)驗(yàn)顯示其能中和MIF的促炎活性，在膿毒癥模型中降低IL-6、TNF-α等細(xì)胞因子水平，改善生存率。

4. **"Epitope mapping of MIF4GD reveals conformational dynamics critical for antibody recognition"**

*作者：Kumar R, et al. (2019)*

*摘要*：通過氫-氘交換質(zhì)譜(HDX-MS)和定點(diǎn)突變分析，揭示了MIF四聚體結(jié)構(gòu)域的動(dòng)態(tài)構(gòu)象變化，并鑒定出抗體結(jié)合的關(guān)鍵氨基酸殘基，為優(yōu)化診斷/治療性抗體提供理論依據(jù)。

**提示**：以上為基于MIF研究的合理推測(cè)，實(shí)際文獻(xiàn)需通過PubMed、Web of Science等平臺(tái)以關(guān)鍵詞“MIF antibody”、“MIF tetramerization domain”或“MIF structural epitope”進(jìn)一步檢索確認(rèn)。若研究方向涉及特定疾病(如癌癥、風(fēng)濕病)，可結(jié)合“MIF + [疾病名稱] + antibody”細(xì)化查詢。

背景信息

MIF4GD antibody targets macrophage migration inhibitory factor (MIF), a multifunctional cytokine involved in inflammation, immune regulation, and cancer progression. MIF is secreted by immune cells, endothelial cells, and tumor-associated cells, acting through receptors like CD74 and CXCRs to activate downstream signaling pathways (e.g., MAPK, PI3K/Akt). It promotes pro-inflammatory responses, cell proliferation, and angiogenesis while inhibiting apoptosis. Dysregulated MIF expression is linked to autoimmune diseases (e.g., rheumatoid arthritis), sepsis, and cancers, making it a therapeutic target.

The MIF4GD antibody specifically recognizes an epitope within the MIF protein, often used to neutralize its activity or detect expression in research. Studies utilize this antibody to investigate MIF's role in disease mechanisms, evaluate its inhibition in preclinical models, or validate diagnostic biomarkers. Its application spans immunoblotting, immunohistochemistry, and functional assays to block MIF-CD74 interactions. Recent research explores MIF4GD's potential in combination therapies, particularly in cancers where MIF-driven pathways confer resistance to conventional treatments. As MIF inhibitors advance into clinical trials, this antibody remains a critical tool for elucidating MIF's complex biology and therapeutic targeting.

關(guān)鍵字： MIF4GD抗體;MIF4GD;MIF4GD Antibody;

公司簡(jiǎn)介

是一家科研、開發(fā)、生產(chǎn)和銷售為一體的科技型企業(yè)，

成立日期	2024-07-02 （2年）	注冊(cè)資本	20萬人民幣
員工人數(shù)	1-10人	年?duì)I業(yè)額	￥ 100萬以內(nèi)
主營行業(yè)	抗體,蛋白組學(xué),細(xì)胞生物學(xué)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

上海切爾齊生物科技有限公司

VIP 1年

公司成立：2年
注冊(cè)資本：20萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：重組蛋白、抗體、生物試劑
公司地址：青浦區(qū)

進(jìn)入店鋪

詢盤

店內(nèi)推薦

TRIP6抗體—艾普蒂

詢價(jià)

FOLR1抗體—艾普蒂

詢價(jià)

alphaTubulin（yeast）抗體—艾普蒂

詢價(jià)